Pfizer/BioNTech vaccine shows promise against Brazil coronavirus variant in laboratory testing
The Brazil variant has been found to spread more quickly than other examples of the coronavirus.
The Pfizer/BioNTech coronavirus vaccine was able to combat the Brazil variant of COVID-19, it has been revealed.
Scientists tested the blood of people who had received the jab and found it fared well against a laboratory made version of the virus similar to the one first discovered in Brazil.
Scientists from the two medical companies and the University of Texas created a version of the virus that had the same spike protein mutations as the P.1 variant.
This is what was tested in the blood of those who had been vaccinated.
The spike protein is the part of the virus used to get into human cells, and many of the vaccines target this part of the virus.
The scientists found the antibodies from the blood was able to neutralise the test virus.
Pfizer has said that it believes its current inoculation is highly likely to still provide protection against the South African variant.
But the pharmaceutical giant is planning to test a third booster dose of its jab as well as creating a version of the drug specifically designed to combat the variant.